Regulation of TTN as a mechanism of and treatment for heart failure

Dominic E. Fullenkamp*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Truncation variants in the gene TTN encoding titin are the most common cause of familial dilated cardiomyopathy (DCM), with both haploinsufficiency and “poison peptide” implicated as contributory mechanisms of disease. In this issue of the JCI, Kim et al. identify a highly conserved enhancer element approximately 500 bp downstream of the transcriptional start site of TTN in intron 1, which they demonstrated to be critical in regulating TTN expression. This work helps to further clarify the relative role of haploinsufficiency in TTN-related DCM and provides a potential target for therapies aimed at treating TTN-related DCM.

Original languageEnglish (US)
Article numbere189335
JournalJournal of Clinical Investigation
Volume135
Issue number4
DOIs
StatePublished - Feb 17 2025

Funding

This work is supported by NIH grant K08 HL163392 (to DEF) and the Leducq Foundation. DEF is a CZ Biohub Chicago Investigator.

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Regulation of TTN as a mechanism of and treatment for heart failure'. Together they form a unique fingerprint.

Cite this